



Vickers Venture Partners leads \$4.3 million funding round in UK-based biotech company SiSaf

SINGAPORE, 4 JUNE 2018 – Singapore headquartered venture capital firm Vickers Venture Partners is announcing their second investment in SiSaf, a commercial stage biopharmaceutical company pioneering a novel method of drug delivery.

This marks the close of an oversubscribed \$4.3 million series A2 Interim funding round for the UK-based company, with Vickers Venture Partners as the lead investor. The investment will help to accelerate pipeline development and build manufacturing capability in dermatology, cosmetic skin care and other therapeutic areas.

Vickers Ventures Partners’s Vice President, Elkhilil Binebine, M.D., who led the investment said, “We look for sustainable business models with competitive edge and leaders with strength of character. Platform plays are key to our portfolio risk mitigation when we are investing. SiSaf optimizes this model; their unique technology has so many potential applications it’s astonishing. The data in multiple areas is incredibly compelling and we are convinced they will change the face of drug delivery.”

Vickers Venture Partners is a second-time investor into SiSaf, following their first investment in the series A1 round of company back in 2016.

SiSaf’s Founder and ProSilic inventor, Dr. Suzanne Saffie-Siebert, Ph.D. said,

“It is great to have Vickers Venture Partners lead this round as a second-time investor. We’re fortunate to have the team at Vickers on board that not only backs us financially, but also takes an advisory role. Vickers’ second investment into the company gives us a sense of positive affirmation and we’re planning to use the fund to further develop our pipeline and manufacturing capabilities. We don’t discover new drugs. Instead, we make existing drugs better, by formulating them with our ProSilic bio-courier technology. We have made it our mission to make these drugs work the way they were meant to work.”

Vickers Venture Partners once again showcases their global footprint with another high value investment into a European company. Founded in 2005 by Dr Finian Tan and four other partners in Singapore, the company now also has offices in Kuala Lumpur, Shanghai, Hong Kong, San Diego and New York. They also recently announced their \$10.4-million investment in the series A round of UK blockchain startup Everledger in March this year.



About SiSaf

SiSaf is a UK HQ'd, commercial stage bio-pharmaceutical company pioneering bio-courier technology, a novel method of drug delivery offering exceptional safety and versatility. In addition to a rich dermatology pipeline, SiSaf also has subsidiaries in high need / high value markets, such as cosmetic skincare and nutraceuticals.

About Vickers Venture Partners:

Vickers Venture Partners is a venture capital firm focused on early-stage investments in Asia and beyond. The firm's portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services. Some of its partners have track records that include hits such as Baidu.com, Inc (NASDAQ: BIDU), Focus Media Holding Ltd (NASDAQ: FMCN), Kongzhong Corp (NASDAQ: KONG), Cambridge Real Estate Investment Trust (SGX: CREIT), Sunfun Info Co. (Gretai: 5278) Asian Food Channel (trade sale), UUCUN (trade sale), TWG Tea (trade sale), RTG Asia (trade sale), JJE (trade sale), Hillstone (trade sale), M-Daq (trade sale), Tenfen (trade sale), Kuyun (trade sale) and Mainspring (trade sale). The total market value of the companies that the partners have helped grow exceeds US\$90 billion today. Vickers Venture Partners announced in October 2017 that they have raised US \$230 million to invest in startups across the world, with a particular focus on Deep Tech across the globe and impact investments in emerging markets.

Vickers Venture Partners was founded by Finian Tan, Khalil Binebine, Jeffrey Chi, Damian Tan, and Linda Li in 2005. It is based in Singapore with offices in Kuala Lumpur, Shanghai, Hong Kong, New York, San Diego with an office opening in San Francisco in 2018.

PR Contact:

REDHILL

malini@redhill.asia